Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Despite recent significant advances in genomic techniques, there are currently no practice guidelines for the clinical implementation of genomics.

The Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI), in association with researchers at the University of Oxford and the Harvard Stem Cell Institute have today published an Opinion piece in Nature Medicine, which recommends the development of ‘Good Genomic Practice’ (GGP) guidelines. Like good laboratory practice (GLP) and good manufacturing practice (GMP), GGP aims to ‘ensure the quality and consistency of medical research and practice’ in the field.

The proposed guidelines would address the ethical, scientific, quality assurance, data handling and storage issues surrounding genomic diagnosis, setting out best practice principles from ‘initial sample collection to the ultimate clinical decision.

Good practice guidelines in this field would result in greater consistency in the reported results as well as an improved understanding of the clinical significance of genetic variants. Not only is this a step towards stratifying medicine; but also the development of integrated global databases with standardized formats, bringing the ultimate goal of truly personalizing treatments closer.

The authors suggest that international leaders in the genomics field should create a checklist to map out the key stages in the process that require standardization and then work with wider stakeholders to formulate guidelines.  Defining the parameters of GGP at this early stage will ensure that the field realizes its ‘boundless potential to improve human health.’


Links:

Original paper in Nature

CASMI

Similar stories

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.

New national study of long-term impacts of debilitating lung damage from COVID-19

Coronavirus COVID-19 General Research

A new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with £2 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.

Opportunities for final goodbyes must be prioritised in COVID-19 pandemic

Coronavirus COVID-19 General Research

Bereaved relatives described the ongoing pain of being absent at the end of a loved-one's life. Many had not seen their relative for weeks or months due to the pandemic. Opportunities must be prioritised for essential connections between families at end-of-life care.